Novavax surprising failure! Dr. Peter McCullough highlights how much the Theoretical Vaccine Effectiveness for Novavax was Unacceptably Low; Real World Study Disappointing for Non-Genetic Vaccine

We had hoped given Novavax was not using the delivery platform that the mRNA technology (or viral vector DNA) vaccines used & delivered a lower dose of spike protein, that it was effective & safe; NO!

McCullough is on point with this Mateo-Urdiales et al. study showing the failure of Novavax:

‘If it came to forced COVID-19 vaccination against human will, I have said Novavax would be the choice since it gives a limited 5 mcg dose of the potentially lethal Spike protein and has no genetic material. The growing number of fatal side effects with mRNA vaccines and recent news of contamination with SV-40 cDNA has resulted in record low rates of booster uptake, currently at 1.3% of unwary Americans.

Mateo-Urdiales reported on 20,903 individuals who took the two shot primary series of Novavax. Theoretical vaccine effectiveness was shockingly low:

“Adjusted estimated vaccine effectiveness against notified SARS-CoV infections in those with partial vaccination (15 days after the first dose to 14 days after the second dose) was 23%(95%CI, 13%-33%), increasing after full vaccination to 31% (95%CI, 22%-39%). Estimated vaccine effectiveness was higher against symptomatic COVID-19, with an estimate of 31% (95%CI, 16%-44%) in those partially vaccinated and of 50% (95%CI, 40%-58%) in those fully vaccinated.”

If a vaccine cannot safely provide at least 50% protection for a year, it is not viable in my clinical practice. Sadly Novavax failed at both of these outcomes. With low-risk Omicron, and likely substantial natural immunity by Fall of 2022, only 26 infections led to hospitalization during the study period; 1 occurred during the reference period, 7 during partial vaccination, and 18 after full vaccination. No deaths were reported.

Mateo-Urdiales A, Sacco C, Petrone D, et al. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19. JAMA Netw Open. 2023;6(10):e2336854. doi:10.1001/jamanetworkopen.2023.36854

In summary, Novavax is probably the safest of all the COVID-19 vaccines because it does not use genetic technology. Sadly, it is useless against Omicron and cannot be recommended for any health benefit.’

Theoretical Vaccine Effectiveness for Novavax Unacceptably Low